Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing

H-J Guchelaar; H Gelderblom; T van der Straaten; J H M Schellens; J J Swen

doi:10.1038/clpt.2014.13

Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing

H-J Guchelaar
, H Gelderblom
, T van der Straaten
, J H M Schellens
, J J Swen

Pharmacoepidemiology and Clinical Pharmacology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.

Original language	English
Pages (from-to)	383-385
Number of pages	3
Journal	Clinical Pharmacology and Therapeutics
Volume	95
Issue number	4
DOIs	https://doi.org/10.1038/clpt.2014.13
Publication status	Published - Apr 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antineoplastic Agents
Genetic Variation
Genome-Wide Association Study
Genomics
High-Throughput Nucleotide Sequencing
Humans
Neoplasms
Pharmacogenetics
Phenotype

Access to Document

10.1038/clpt.2014.13

Cite this

@article{125ae6c1fefe416fa8a3c833e03b12bd,

title = "Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing",

abstract = "Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.",

keywords = "Antineoplastic Agents, Genetic Variation, Genome-Wide Association Study, Genomics, High-Throughput Nucleotide Sequencing, Humans, Neoplasms, Pharmacogenetics, Phenotype",

author = "H-J Guchelaar and H Gelderblom and \{van der Straaten\}, T and Schellens, \{J H M\} and Swen, \{J J\}",

year = "2014",

month = apr,

doi = "10.1038/clpt.2014.13",

language = "English",

volume = "95",

pages = "383--385",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Pharmacogenetics in the cancer clinic

T2 - from candidate gene studies to next-generation sequencing

AU - Guchelaar, H-J

AU - Gelderblom, H

AU - van der Straaten, T

AU - Schellens, J H M

AU - Swen, J J

PY - 2014/4

Y1 - 2014/4

N2 - Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.

AB - Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.

KW - Antineoplastic Agents

KW - Genetic Variation

KW - Genome-Wide Association Study

KW - Genomics

KW - High-Throughput Nucleotide Sequencing

KW - Humans

KW - Neoplasms

KW - Pharmacogenetics

KW - Phenotype

U2 - 10.1038/clpt.2014.13

DO - 10.1038/clpt.2014.13

M3 - Article

C2 - 24448475

SN - 0009-9236

VL - 95

SP - 383

EP - 385

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 4

ER -

Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this